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field, but even today there is confusion. 
The European Academy of Allergy and 
Clinical Immunology (EAACI) published 
a new allergy nomenclature in 2001. In 
this nomenclature, “atopic eczema/der-
matitis syndrome” (AEDS) was proposed 
as an overarching term to replace both 
AD and AE (Johansson et al., 2001). The 
nomenclature was then reviewed by the 
World Allergy Organization (WAO) in 
2004, when “eczema” replaced AEDS, 
with AE reserved for cases with evidence 
of allergic sensitization to environmental 
allergens (Johansson et al., 2004; Figure 
2). However, this suggested change has 
not been adopted uniformly. It ruffled 
feathers in particular in countries where 
eczema is a more general term for skin 
rashes, and the dermatology community 
has consequently continued to use AD, 
AE, and eczema interchangeably.
That alone would not be a disaster 
because the name by which we call the 
beast is less important than the compa-
rability of diagnostic criteria and study 
outcome measures. Brenninkmeijer et al. 
(2008) recently published a systematic 
review of the current diagnostic criteria 
for AD, highlighting the urgent need for 
consensus. Following publication of the 
landmark diagnostic criteria presented 
by Hanifin and Rajka in 1980, which to 
date remain the most commonly used 
There has been a significant increase in 
the prevalence of atopic dermatitis (AD) 
recently, with about 15–20% of children 
in developed countries currently affected 
by the disease (Odhiambo et al., 2009). 
AD also affects between 2 and 15% of 
adults in industrialized countries (Herd 
et al., 1996; Vartiainen et al., 2002). 
The financial burden on patients, their 
families, and the health-care system and 
quality of life impairment are significant 
(McKenna et al., 2007); taken together, 
this has contributed to a heightened 
interest in AD-related research. Not sur-
prisingly, therefore, the AD literature 
has grown considerably (Figure 1). This 
must be welcomed, but often quantity 
does not translate directly into quality, 
and, what is more, direct comparabil-
ity among studies (for instance as part of 
meta-analyses and quality assessment) 
is only possible if universal validated 
diagnostic criteria and outcome tools 
are used. Unfortunately, the dermatology 
community has been speaking in many 
tongues when it comes to AD.
the mess we are in
Terms like “prurigo diasthésique” and 
“mycosis flexurarum” are (thankfully) 
echoes of a bygone era, and decades 
ago AD and atopic eczema (AE) became 
the most commonly used terms in the 
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The past 2 decades have seen a heightened interest in atopic dermatitis–related 
research, leading to an exponential increase in publications. However, large num-
bers of diagnostic criteria and outcome measures hamper study comparability. 
The Harmonizing Outcome Measures for Eczema (HOME) initiative addresses the 
urgent need for consensus, but more work will be required.
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diagnostic criteria for AD, an additional 
eight criteria have been published. It is 
important to remember that the Hanifin 
and Rajka criteria were based on expert 
consensus, and only the UK refinement 
of those criteria has been validated in 
both hospital and community settings 
(Brenninkmeijer et al., 2008). They are 
also the only diagnostic criteria to have 
been independently validated. Valid 
diagnostic criteria suitable for hospital 
studies as well as large population-based 
surveys should be part of the foundation 
on which we build epidemiological, lab-
oratory, and clinical trial research. Valid, 
reliable, and relevant outcome measures 
must form the other part of this founda-
tion, and we as dermatology researchers 
have the responsibility to ensure they are 
put in place.
How do we get out of the mess?
A systematic review of AD severity mea-
surement tools found that 91% of AD 
clinical trials used an objective severity 
measure but that only one-third of these 
scales had been published (Charman 
et al., 2003). Schmitt et al. (2007) con-
sequently assessed the validity and reli-
ability of the 20 most common severity 
measures for AD, and only 3 performed 
adequately. This then triggered an interna-
tional Delphi exercise on outcome mea-
sures for AD—Harmonizing Outcome 
Measures for Eczema (HOME), published 
by Schmitt et al. (2011, this issue)—
in an attempt to ensure investigators 
employ a core set of outcome measures. 
Modeled on the OMERACT initiative 
for joint diseases (Tugwell et al., 2007), 
the HOME panel consisted not only of 
clinical experts but also of consumers, 
editors of US and European dermatol-
ogy journals, and a regulatory agency 
representative. Consensus was achieved 
for universal inclusion of AD symptoms, 
physician-assessed clinical signs, and 
a measure of long-term control of flares 
as core outcome measures. Interestingly, 
and in contrast to all other stakeholders, 
the majority of consumers did not think 
that impact on quality of life needed to 
be assessed in all AD clinical trials. Of 
course, this consensus represents only 
the minimum set of outcome measures; 
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others, depending on the circumstances, 
can be added by investigators as they 
see fit. It is important to emphasize that 
none of the panel members had a vested 
interest in a specific outcome measure 
or significant links to the pharmaceutical 
industry.
HOME is a welcome and timely ini-
tiative, but it is only the first step in the 
right direction. Future HOME Delphi 
rounds will need to address a much 
more delicate task: developing agree-
ment on the tools used to assess the 
three identified core outcome domains. 
Even then, much more remains to be 
done, such as seeking agreement on 
diagnostic criteria. Only then will we as 
dermatologists be wise, rather than fool-
ish builders of our own research founda-
tions, for the benefit of evidence-based 
dermatology and our patients.
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Clinical Implications
•  A multitude of diagnostic criteria and severity scores for atopic 
dermatitis exist.
•  Only uniform, valid, and reliable diagnostic criteria and outcome 
measures will allow direct comparison of epidemiological and clinical 
study results (i.e., as part of meta-analyses).
•  Based on an international Delphi exercise, the Harmonizing Outcome 
Measures for Eczema (HOME) initiative has identified atopic dermatitis 
symptoms, physician-assessed clinical signs, and a measure of long-
term control of flares as core outcome measures.
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Prospects for Skin Cancer Treatment 
and Prevention: The Potential 
Contribution of an Engineered Virus
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nonmelanoma skin cancers are among the most common human malignancies. 
Although typically not lethal, they are responsible for tissue deformity and 
substantial morbidity, particularly in high-risk populations. Solar UVB radiation—
a major etiologic factor for this kind of malignancy—produces DnA lesions such 
as cyclobutane pyrimidine dimers and 6-4 photoproducts in skin. These lesions 
are removed through nucleotide excision repair because humans lack a DnA 
glycosylase required to initiate base excision repair of pyrimidine–pyrimidine 
photoproducts but produce all the other proteins required for this process. In this 
issue, Johnson et al. show that a DnA glycosylase derived from Chlorella virus and 
engineered to enhance tissue penetration and nuclear localization can remove 
UVB-induced DnA lesions in a human skin equivalent model and that the protein 
can be incorporated into a topical formulation for the prevention and treatment 
of UVB-induced DnA damage. These results suggest that such an enzyme may be 
incorporated into regimens for the chemoprevention of skin cancers.
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When UVR interacts with skin, it 
produces photochemical changes in 
DNA that can adversely affect the skin’s 
bio logical activities and produce disease. 
Two lesions most commonly result from 
UVR exposure: cyclobutane pyrimidine 
dimers (CPDs), in which adjacent 
pyrimidine rings are coupled through 
carbon–carbon double bonds at the 5 
and 6 positions, and 6,4-pyrimidine 
pyrimidone photoproducts, in which 
adjacent pyrimidines are connected 
through a single bond between the 6 
position of one molecule and the 4 
position of the other. These alterations, 
if not restored to their original state, 
produce mutations that can ultimately 
lead to non melanoma skin cancers 
(NMSCs), including both squamous 
cell (SCCs) and basal cell carcinomas 
(BCCs) (Cleaver and Crowley, 2002). 
Fortunately, virtually all living organisms 
possess intricate repair mechanisms 
to mend damaged DNA. Bulky lesions 
such as CPDs are normally repaired by 
nucleotide excision repair, but they can 
also be restored by base excision repair 
(BER). Humans, however, can repair 
CPDs only through nucleotide exci-
sion repair (NER). Although human cells 
have most of the enzymes necessary to 
complete BER, they lack an important 
DNA glycosylase required to initiate 
the process (Cafardi and Elmets, 2008). 
The importance of DNA repair for pro-
tection from UV-induced skin cancers 
is evident if one examines individuals 
who suffer from xeroderma pigmento-
sum (XP), an inherited disease in which 
the NER pathway of DNA is deficient. 
These patients have a propensity to 
develop extensive photodamage, cuta-
neous SCCs, BCCs, and melanomas at 
an unusually early age.
Even in healthy individuals NMSCs 
are particularly common. In the United 
States alone, the estimated 1.5–3.5 mil-
lion new NMSC diagnoses each year 
exceed those of all other types of cancer 
combined. Although rarely lethal, these 
lesions are locally destructive and the 
cost of their removal represents an eco-
nomic burden to the healthcare system. 
The direct cost for treatment of NMSCs 
in the United States was estimated to be 
$1.5 billion in 2004, and if actinic ker-
atoses—premalignant lesions that may 
progress to SCCs—were included, the 
direct cost would increase to over $2.3 
billion (Bickers et al., 2006). In contrast 
to most other malignancies, in which 
the incidence has stabilized or declined, 
the rate of NMSCs continues to rise 
(Athas et al., 2003; Karagas et al., 1999). 
Moreover, in a population-based retro-
spective study from 1976 to 2003, the 
incidence of BCCs and SCCs in patients 
under 40 years old was found to be 
increasing significantly (Christenson et 
al., 2005).
Efforts to prevent actinic keratoses and 
NMSCs have been directed at counseling 
patients to limit the amount of UVR that 
reaches the skin, either through avoid-
ance of sun exposure and tanning bed use 
or through the application of sunscreens. 
The American Academy of Dermatology, 
the American Cancer Society, and other 
organizations throughout the world have 
developed sophisticated educational 
